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Making a diagnosis is an important process in medicine. 
Performing a diagnostic test will ascertain the presence 
of a disease as a cause of a health problem. The value of 
test results depends both on the diagnostic performance 
and how the results will improve the outcome of illness. 
Diagnostic performance means that the test should 
evaluate what it intends to assess, and that repeated 
measurements give similar results. Besides performance, 
the diagnostic test will be chosen because of several other 
factors such as preferences, availability, experience, costs 
and so on. 
Inappropriate diagnostic testing may have serious 
consequences for individual patients. To prevent the 
implementation of disappointing new diagnostic tests it 
is necessary to conduct appropriate assessment studies. In 
the current issue of the Netherlands Journal of Medicine, 
colleague van Keeken from Bernhoven Hospital, Oss, 
the Netherlands presents a study in which she and her 
colleagues evaluated a new rapid urease test (GUT test) 
to diagnose Helicobacter pylori infection.1 Guidelines have 
been put forward for evaluating new diagnostic tests.2 
According to these guidelines three aspects are of major 
importance: selection of an appropriate patient population, 
determination of the diagnostic performance and the 
relation with existing diagnostic tests. Let us apply these 
aspects to van Keeken’s study. 
C l i N i C A l  i N d i C A T i o N 
The initial challenge lies in the selection of an adequate 
patient population. The risk of not using the appropriate 
patient population is that the large contrast between 
severely ill patients and healthy individuals will 
overestimate the test performance. What is the appropriate 
patient population for a H. pylori test? The infection 
is without doubt involved in several diseases: peptic 
ulcer disease, gastric cancer and B cell lymphoma.3 The 
impact of H. pylori infection and functional dyspepsia 
is more controversial. H. pylori eradication does appear 
to be beneficial for a small subgroup of patients with 
functional dyspepsia.4 Thus, the indication to use the test 
is patients suspected of having peptic ulcer disease, gastric 
cancer, B cell lymphoma and in all probability functional 
dyspepsia. This, however, means that patients referred 
for upper gastrointestinal endoscopy are not the indicated 
study population. The patient population evaluated in this 
study consisted of 116 consecutive patients who underwent 
an upper gastrointestinal endoscopy. More data about 
the indication for H. pylori infection testing or upper 
gastrointestinal endoscopy were not given. Because of this 
lack of information about the reason for testing it is not 
possible to judge whether the test has been evaluated in an 
adequate patient population. 
d i A g N o s T i C  p E r f o r M A N C E 
There are several ways to handle the diagnostic test results 
from an assessment study. For qualitative tests sensitivity, 
specificity, and positive and negative predictive value 
are the most used test outcome measures. The major 
problem with assessment of the diagnostic performance 
of the H. pylori test is the absence of a test determining 
the definitive disease status (gold standard). As a result 
in some studies inappropriate tests are being used as a 
reference. In this study the authors have overcome the 
problem by comparing the new test directly with another 
rapid urease test (CLO test), and with the combination 
of bacterial culture and histology. Previous research has 
shown that using a combination of biopsy-based tests 
represents an appropriate reference standard to diagnose 
H. pylori infection.5 
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C o N T r i b u T i o N  o f  T h E  N E w  T E s T 
When it becomes clear that the diagnostic performance 
is adequate in the indicated patient population it is 
important to establish the contribution of the new test to 
the existing diagnostic arsenal. At the moment several 
methods can be used to diagnose H. pylori infection, both 
biopsy based and nonbiopsy based. The rapid urease test 
evaluated in this study requires an upper gastrointestinal 
endoscopy for retrieval of a biopsy specimen. The other 
biopsy-based tests are bacterial culture and histology. The 
results from the study showed that the overall diagnostic 
performances of the evaluated biopsy-based tests were not 
statistically different. So other aspects of the new test are 
of importance. The authors state that the new rapid urease 
test has a more rapid reaction time and is much cheaper. 
The outcome of the new rapid urease test (GUT test) 
was reliable 60 minutes after endoscopy in comparison 
with 24 hours for the other urease test (CLO test) and 
several days for culture and histology. It is, however, 
questionable whether this gain of time has significant 
clinical consequences. Another important aspect is the 
lower costs of the test in comparison with other rapid 
urease tests. H. pylori infection is still a major health 
problem worldwide.6 A cheaper diagnostic test with equal 
clinical effects might lead to significantly lower overall 
medical costs. 
C o N C l u s i o N
The new more rapid urease test seems to be a promising 
new diagnostic test with equal diagnostic performance 
but considerably lower costs and a faster availability of 
the test results, in comparison with other biopsy-based 
H. pylori tests. Whether the gain in time and lower costs 
are sufficient to switch from the old but well-known other 
rapid urease tests to this new more rapid GUT test depends 
on the priorities and preferences of the users. However, 
before implementation the results from this study have to 
be confirmed, including the additional value of the new test 
to the entire diagnostic process and the cost-effectiveness. 
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